CATHERINE MARTINEZ: Open Payments
NPI 1881368405 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$995 in 46 payments from 16 companies in 2025. Trend: 2023 $35 · 2024 $1,270 · 2025 $995
Food & beverage: $995
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $153 |
| Novartis Pharmaceuticals Corporation | 4 | $140 |
| Amgen Inc. | 6 | $121 |
| Fresenius USA Marketing, Inc. | 4 | $85 |
| Mallinckrodt Hospital Products Inc. | 4 | $80 |
| Novo Nordisk Inc | 3 | $77 |
| Apellis Pharmaceuticals, Inc. | 3 | $56 |
| OPKO Pharmaceuticals, LLC | 3 | $54 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
Products named: TAVNEOS, FARXIGA, Vanrafia, VELPHORO, Ozempic, RAYALDEE, ACTHAR, JYNARQUE.
Industry payments across MS — which companies pay providers there.
